Checking all the boxes
- Independent third party analysis by Cawthron and Callaghan Innovation.
- Fatty acid analysis and lengthy stability trials.
- Heavy metal screen: Inorganic Arsenic, lead, cadmium and mercury all less than .1ppm
- Pesticide screens less than .02 ppm.
- Microbial screen negative for pathogens
- Safety studies demonstrating no adverse effects.
Each capsule provides 1.7 kcal and consists of 99.7% lipid (50mg of Antinol® PCSO-524® and 100 mg of olive oil for improved extract bioavailability). DHA and EPA account for 10.4% while total PUFAs consisting of additional omega 3s, unique omegas and omega 6s account for 19.54% of the bioactive lipid profile. Vitamin E is present in small but sufficient quantities to prevent fatty acid oxidation. There are no significant quantities of Vitamin A or trace minerals. There is less than .1% carbohydrate and a trace of protein in the lipid extract. Capsules contain bovine based gelatin.
Adverse Reactions to Food?
Reactions to gelatin are considered extremely uncommon. Trace amounts of protein within the capsules are not expected to elicit an allergic response when managing adverse reactions to food. If you have a very reactive or sensitive patient you can pierce the capsule and express the contents onto the food.
Fat Intolerant Conditions?
Pancreatitis and Protein Losing Enteropathy (PLE) are two common fat intolerant conditions in dogs. Antinol® as prescribed for mobility and osteoarthritis is based on a 5mg/kg loading dose and a 2.5mg/kg maintenance dose. For dogs under 40 pounds this logistically means two capsules or 300 mg of lipid per day at the loading dose and for dogs over 40 pounds this equals 4 capsules or 600 mg of lipid per day. In stable patients on a typical low fat veterinary prescription diet it is possible to add Antinol® to the diet and stay within the lower end of the range for daily fat intake on a grams/1000 kcal basis. In patients that are acutely ill, recently diagnosed, require a board certified nutritionist designed ultra-low fat homemade diet, or have challenging or refractory disease than Antinol® should be reserved for a later date and discussion. All supplements in patients with concurrent disease should receive the approval of your veterinarian!
Copper Storage Liver Disease?
Many of our active and adventurous breeds that can benefit from osteoarthritis prevention or treatment are also at risk of copper storage hepatopathy. Any breed can potentially develop copper storage hepatopathy but Labrador Retrievers, Dalmatians, and Dobermans stand out among the large breed dogs. There is no detectable copper or zinc found in Antinol®.
A published safety study has demonstrated Antinol® has been evaluated in healthy Beagles at 10 times the loading dose. There were no significant changes in the Complete Blood Count (CBC), Biochemistry panel or Clotting Times (Thrombin time, Prothrombin time or Activated Partial Thromboplastin time).
Heart Failure or Kidney Disease ?
In both of these conditions, key nutrients of concern include sodium and phosphorus. Sodium is of particular concern in congestive heart failure patients. Dietary phosphorus restriction is a key part of prolonging the lives of patients with chronic renal disease. Antinol® adds no significant sodium (< 8 ppm) or phosphorus (<10 ppm) to the diet and may provide specific benefits to patients with cardiac and glomerular disease.
Learn more at www.antinolstudies.com
Reach out with any questions here.